Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Investigate Safety and Tolerability of Higher Infusion Rate to shORten the duraTion of FabrazymE Infusion

NCT06019728 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06019728
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06019728 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Investigate Safety and Tolerability of Higher Infusion Rate to shORten the duraTion of FabrazymE Infusion
Lead sponsor
Sanofi
Phase
Phase 4
Overall status
Completed
Start date
November 10, 2023
Completion date
October 25, 2024
Enrollment
8 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

fabry's disease